| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:L-I-OddU
CAS:207920-87-4
Package:25mg/RMB 14900;50mg/RMB 19420;100mg/RMB 24625
|
| Company Name: |
Shanghai meikai technology co., ltd
|
| Tel: |
021-68689288 15300790979 |
| Email: |
info@mkbio.com.cn |
| Products Intro: |
Product Name:1-((2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-5-iodopyrimidine-2,4(1H,3H)-dione
CAS:207920-87-4
Purity:98% Package:100mg;250mg;1g
|
|
| | 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-iodo- Basic information |
| Product Name: | 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-iodo- | | Synonyms: | 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-iodo-;L-I-OddU;1-((2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-5-iodopyrimidine-2,4(1H,3H)-dione | | CAS: | 207920-87-4 | | MF: | C8H9IN2O5 | | MW: | 340.07 | | EINECS: | | | Product Categories: | | | Mol File: | 207920-87-4.mol | ![2,4(1H,3H)-Pyrimidinedione, 1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-iodo- Structure](CAS/20210305/GIF/207920-87-4.gif) |
| | 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-iodo- Chemical Properties |
| Melting point | 223 °C (decomp) | | density | 2.17±0.1 g/cm3(Predicted) | | pka | 7.83±0.10(Predicted) |
| | 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-iodo- Usage And Synthesis |
| Uses | L-I-OddU, a L-5'-halo- dioxolane nucleoside analogue, is a potent and selective anti-Epstein-Barr virus (EBV) agent with an EC50 value of 0.03μM. L-I-OddU has low cytotoxicity with a CC50 value of 1000 nM. L-I-OddU has antiviral activity by suppressing replicative EBV DNA and viral protein synthesis[1][2]. | | References | [1] Kira T, et, al. Anti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinase. Antimicrob Agents Chemother. 2000 Dec;44(12):3278-84. DOI:10.1128/AAC.44.12.3278-3284.2000
[2] Focher F, et, al. Antivirals at the mirror: the lack of stereospecificity of some viral and human enzymes offers novel opportunities in antiviral drug development. Curr Drug Targets Infect Disord. 2003 Mar;3(1):41-53. DOI:10.2174/1568005033342163 |
| | 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-iodo- Preparation Products And Raw materials |
|